Histone deacetylases

被引:346
作者
Marks, PA
Miller, T
Richon, VM
机构
[1] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA
[2] Aton Pharma Inc, Tarrytown, NY USA
关键词
D O I
10.1016/S1471-4892(03)00084-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Post-translational modification of the histories of chromatin has a fundamental role in regulating gene expression. Enzymes involved in these epigenetic events include histone deacetylases (class I and class II), which can be inhibited by a structurally diverse group of small molecules. These histone deacetylase inhibitors induce growth arrest, differentiation and/or apoptosis of cancer cells in vitro and in vivo. Results of clinical trials with several of these agents have indicated that they are well tolerated at doses that have anti-tumour activity.
引用
收藏
页码:344 / 351
页数:8
相关论文
共 52 条
  • [11] Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin
    Furumai, R
    Komatsu, Y
    Nishino, N
    Khochbin, S
    Yoshida, M
    Horinouchi, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) : 87 - 92
  • [12] Glaser KB, 2003, MOL CANCER THER, V2, P151
  • [13] Deacetylase enzymes: biological functions and the use of small-molecule inhibitors
    Grozinger, CM
    Schreiber, SL
    [J]. CHEMISTRY & BIOLOGY, 2002, 9 (01): : 3 - 16
  • [14] Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening
    Grozinger, CM
    Chao, ED
    Blackwell, HE
    Moazed, D
    Schreiber, SL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) : 38837 - 38843
  • [15] Translating the histone code
    Jenuwein, T
    Allis, CD
    [J]. SCIENCE, 2001, 293 (5532) : 1074 - 1080
  • [16] The fundamental role of epigenetic events in cancer
    Jones, PA
    Baylin, SB
    [J]. NATURE REVIEWS GENETICS, 2002, 3 (06) : 415 - 428
  • [17] KELLY W, 2003, IN PRESS CLIN CANC R
  • [18] Histone deacetylase inhibitors: from target to clinical trials
    Kelly, WK
    O'Connor, OA
    Marks, PA
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (12) : 1695 - 1713
  • [19] Functional significance of histone deacetylase diversity
    Khochbin, S
    Verdel, A
    Lemercier, C
    Seigneurin-Berny, D
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2001, 11 (02) : 162 - 166
  • [20] Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
    Kim, YB
    Lee, KH
    Sugita, K
    Yoshida, M
    Horinouchi, S
    [J]. ONCOGENE, 1999, 18 (15) : 2461 - 2470